Free Trial

Adaptimmune Therapeutics (ADAP) Earnings Date, Estimates & Call Transcripts

Adaptimmune Therapeutics logo
$0.60 +0.00 (+0.82%)
(As of 12/20/2024 05:51 PM ET)
Get Adaptimmune Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ADAP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADAP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Adaptimmune Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.12-$0.12-$0.12
Q2 20242-$0.17$0.18$0.00
Q3 20243-$0.24-$0.10-$0.17
Q4 20243-$0.17-$0.07-$0.12
FY 20249-$0.70-$0.11-$0.40
Q1 20251-$0.18-$0.18-$0.18
Q2 20251-$0.12-$0.12-$0.12
Q3 20251-$0.12-$0.12-$0.12
Q4 20251-$0.12-$0.12-$0.12
FY 20254($0.54)($0.54)($0.54)

Adaptimmune Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/12/2024Q2 2024-$0.27+$0.27$0.27$58.00M$128.23M
5/15/2024Q1 2024-$0.16-$0.18 -$0.02-$0.18$4.40M$5.68M
3/6/2024Q4 2023-$0.12-$0.24 -$0.12-$0.24$4.80M$0.23M
11/8/2023Q3 2023-$0.20-$0.20--$0.20$5.00M$7.32M
8/9/2023Q2 2023-$0.17-$0.21 -$0.04-$0.30$5.00M$5.13M
5/12/2023Q1 2023-$0.19$0.01+$0.20$0.01$7.70M$47.60M
3/6/2023Q4 2022-$0.25-$0.18+$0.07-$0.18$7.50M$11.03M

Adaptimmune Therapeutics Earnings - Frequently Asked Questions

Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded annual revenue of $175.04 million.

Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded net income of -$113.87 million. ADAP has generated -$0.22 earnings per share over the last four quarters.

Adaptimmune Therapeutics's earnings are expected to decrease from ($0.14) per share to ($0.48) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:ADAP) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners